Site Editor
Joyce F. Liu, MD, MPH
Joyce F. Liu, MD, MPH
Posted: Monday, June 15, 2026
Adding chiauranib to weekly paclitaxel significantly prolonged progression-free survival compared with placebo plus weekly paclitaxel in patients with primary platinum-refractory or platinum-resistant ovarian cancer, according to results of the phase III CHIPRO trial presented at the 2026 ASCO Annual Meeting (Abstract LBA5504).
Chiauranib is an oral multi-kinase inhibitor that targets Aurora B, VEGFR1/2, PDGFRα/β, and CSF-1R, acting on tumor cell proliferation, neoangiogenesis, and the immunosuppressive tumor microenvironment. In the randomized, double-blind, placebo-controlled CHIPRO trial, 459 patients with epithelial ovarian, fallopian tube, and primary peritoneal cancer were randomly assigned 1:1 to receive weekly paclitaxel with either chiauranib or placebo for up to six cycles, followed by maintenance chiauranib or placebo. Stratification factors included prior lines of chemotherapy and platinum-free interval. Dual primary endpoints were progression-free survival per blinded independent review committee and overall survival.
At a median follow-up of 16.0 months, median progression-free survival was 4.57 months in the chiauranib arm vs 2.69 months in the placebo arm (hazard ratio [HR] = 0.427; 95% confidence interval [CI] = 0.34–0.54; log-rank P < .001), representing a 57% reduction in the risk of progression or death. The progression-free survival benefit was consistent regardless of prior antiangiogenic exposure.
Median overall survival did not differ significantly between groups (12.09 vs 12.12 months; HR = 0.932; 95% CI = 0.73–1.20; log-rank P = .583). However, presenting author Xiaohua Wu, MD, of Fudan University Shanghai Cancer Center, Shanghai, China, noted that there was a significant overall survival benefit observed among patients who did not receive subsequent anticancer therapy (HR = 0.599; 95% CI = 0.39–0.91; log-rank P = .016). Favorable survival trends were also found for patients previously treated with PARP inhibitors.
The overall response rate was 32.0% in the chiauranib arm vs 14.3% in the placebo arm (P < .001), and 76.8% of patients in the chiauranib arm experienced tumor reduction vs 42.4% in the placebo arm. The median duration of response was 5.52 months and 4.14 months in the chiauranib and placebo arms, respectively (P = .093).
The most common grade 3 or higher treatment-emergent adverse events in the chiauranib arm were leukopenia, neutropenia, and anemia. The safety profile was manageable, and no new safety signals were identified. Notably, no patients discontinued treatment due to hypertension or proteinuria.
Disclosure: The study was funded by Chipscreen Biosciences Ltd.
JNCCN Spotlights
